Upstart stock is back in Wall Street’s drama zone: insider buying, massive short interest, AI lending growth, cash-flow concerns, and a possible bank-charter catalyst. High risk? Absolutely. Boring? Not even close.

Read entire article

Charter Communications (CHTR) is down ~79% from its highs but trades at just 4x earnings. With insider buying, heavy short interest, and massive buybacks, is this a deep value play—or a cable trap?

Read entire article

Home BancShares may not be flashy, but the CEO’s $2.7 million stock purchase, cheap valuation, and steady banking fundamentals make HOMB a compelling slow-and-solid compounder to watch in 2026.

Read entire article

Badger Meter just took a 24% hit—but the CEO is buying the dip. With strong long-term water infrastructure trends and improved valuation, is BMI a hidden opportunity or just treading water?

Read entire article

Shoe Carnival (SCVL) is trading near lows with a $500K insider buy, high short interest, and ultra-cheap valuation. Is this a hidden value play—or a classic trap? 👟

Read entire article

Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.

Read entire article

Vail Resorts (MTN) just endured one of the worst snowfall seasons in decades—yet insiders are buying millions in stock. With a powerful Epic Pass model, heavy institutional ownership, and rising short interest, this mountain stock may be setting up for a contrarian move.

Read entire article